About this Research Topic
Nanomedicine in recent years has demonstrated a number of biomedical promises in the treatment of cancer and infection, development of vaccines of various types, delivery of genetic therapeutics and so forth. Meanwhile, the translation of advanced nanotechnology to clinic has been slowed down due to the challenges and limitations towards in vivo delivery, chemistry, manufacturing and controls (CMC), clinical efficacy and safety. These will require more comprehensive understanding in physicochemical properties of nanomaterials and the identification of key characteristics in human physiology and pathophysiology. Further success in pharmaceutical development and mass production of nanomedicines will also accelerate their availability to clinical evaluation and regulatory approval for enhancing patient outcomes.
The goal of this Research Topic is to offer an opportunity of better bridging the basic science research and clinical translation for current nanomedicine development. To fill the gap in scientific advances and clinical practice may increase the success rate of clinical nanomedicine development while effectively decreasing the consumption of resources, thus lower the overall cost throughout the healthcare process. The joint efforts in nanoscience, biomedical and pharmaceutical research are much needed to overcome the multiple obstacles in the critical path of nanomedicine translation. Discussions and communications are warmly welcomed among research scientists, chemical and medical engineers, regulatory representatives, physicians and patients. We welcome Original Research, Review, Mini Review and Perspective articles on themes including, but not limited to:
• Understandings of physicochemical properties of nanomaterials that improve the stability, bioavailability, delivery and therapeutic effect, and safety
• Discoveries in nano-bio interactions, nanomedicine transport in vivo, and related physiology/pathophysiology
• Emerging techniques and method optimization in the characterization, production and purification of nanomaterial-based therapeutics
• Lessons learnt in the clinical investigation of nanomedicines and nanoformulations
• Potential approaches to improving quality control and regulatory guidelines, to establishing widely acceptable international standards, and to facilitating nanomedicine translation
The goal of this Research Topic is to offer an opportunity of better bridging the basic science research and clinical translation for current nanomedicine development. To fill the gap in scientific advances and clinical practice may increase the success rate of clinical nanomedicine development while effectively decreasing the consumption of resources, thus lower the overall cost throughout the healthcare process. The joint efforts in nanoscience, biomedical and pharmaceutical research are much needed to overcome the multiple obstacles in the critical path of nanomedicine translation. Discussions and communications are warmly welcomed among research scientists, chemical and medical engineers, regulatory representatives, physicians and patients. We welcome Original Research, Review, Mini Review and Perspective articles on themes including, but not limited to:
• Understandings of physicochemical properties of nanomaterials that improve the stability, bioavailability, delivery and therapeutic effect, and safety
• Discoveries in nano-bio interactions, nanomedicine transport in vivo, and related physiology/pathophysiology
• Emerging techniques and method optimization in the characterization, production and purification of nanomaterial-based therapeutics
• Lessons learnt in the clinical investigation of nanomedicines and nanoformulations
• Potential approaches to improving quality control and regulatory guidelines, to establishing widely acceptable international standards, and to facilitating nanomedicine translation
Keywords: Nanomedicine, Drug Delivery, Pharmaceutical Development, Therapeutics, Clinical Trials
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
